Regeneron Pharmaceuticals, Inc.REGNNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank26
Year-over-Year Change
Year-over-year operating cash flow growth rate
Percentile
P26
Within normal range
vs 5Y Ago
0x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -27.68% |
| Q3 2025 | 41.45% |
| Q2 2025 | 9.50% |
| Q1 2025 | -17.24% |
| Q4 2024 | -2.20% |
| Q3 2024 | 264.75% |
| Q2 2024 | -76.60% |
| Q1 2024 | 38.80% |
| Q4 2023 | -2.21% |
| Q3 2023 | 8.99% |
| Q2 2023 | -25.24% |
| Q1 2023 | -20.48% |
| Q4 2022 | 173.48% |
| Q3 2022 | 11.43% |
| Q2 2022 | -73.15% |
| Q1 2022 | -11.41% |
| Q4 2021 | -30.50% |
| Q3 2021 | 444.69% |
| Q2 2021 | -6.25% |
| Q1 2021 | -45.69% |
| Q4 2020 | 584.07% |
| Q3 2020 | -126.96% |
| Q2 2020 | 35.16% |
| Q1 2020 | -11.35% |
| Q4 2019 | 41.29% |
| Q3 2019 | 195.96% |
| Q2 2019 | -79.01% |
| Q1 2019 | 23.08% |
| Q4 2018 | 60.92% |
| Q3 2018 | 14.77% |
| Q2 2018 | -36.23% |
| Q1 2018 | 9.15% |
| Q4 2017 | 36.67% |
| Q3 2017 | 1456.99% |
| Q2 2017 | -108.59% |
| Q1 2017 | -5.82% |
| Q4 2016 | -41.96% |
| Q3 2016 | 62.96% |
| Q2 2016 | 787.99% |
| Q1 2016 | -84.04% |